Business Wire

GALDERMA

Share
Galderma Debuts The Sensitive Skincare Faculty, a Global Expert Group to Improve Understanding and Management of Sensitive Skin

Reinforcing its commitment to advancing dermatology for every skin story, Galderma announced today the formation of a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives through focusing on three key pillars of research, innovation and engagement that play a key role in improving the broad understanding and management of sensitive skin. Comprised of 13 experts from across the world, the group will have representation from diverse geographies including China, Brazil, the Philippines, Germany, France, Australia, Italy and the United States (U.S.).

 

“We want people to feel in control of their skin, and this is especially important for those who have skin conditions that are often misunderstood – like sensitive skin.
We’re delighted to bring together such an esteemed group of experts from around the world who will collaborate to propose and implement research, innovation and educational projects
to advance the science of sensitive skin and bring positive changes to the whole community.”

 

WALTER GEIGER
CONSUMER CARE GLOBAL BUSINESS UNIT HEAD, GALDERMA

 

Sensitive skin is a complex and often interconnected condition, requiring personalized care and products specifically designed for it. More than seventy percent of people worldwide diagnose themselves as having sensitive skin, which can negatively impact quality of life and leave them feeling frustrated and looking for better solutions.i There is a need for science-backed guidance and advice on how to identify and care for sensitive skin of all kinds, to help improve the overall quality of sensitive skin.

The Sensitive Skincare Faculty will focus on three core pillars of activities:

  • Research – expanding the understanding of sensitive skin by filling evidence gaps and advancing in emerging areas
  • Innovation – inspiring the development of new solutions to improve diagnosis and care
  • Engagement – enhancing the knowledge of healthcare professionals to shape the future of best practice

In partnership with the Department of Dermatology at the George Washington University School of Medicine and Health Sciences, two grants have been awarded to accelerate the mission of the Sensitive Skincare Faculty. The first will establish a Galderma Sensitive Skin Translational Research Fellowship Program over five years to support medical students interested in expanding their research skill set into sensitive skin. The second project, the Galderma Skin Research Acceleration Fund, will span two years and look specifically at establishing a standard definition of sensitive skin.

 

“Our goal is to transform the science of sensitive skin into actionable insights and practical advice
that will empower everyone – from consumers and patients to healthcare professionals – to make positive strides forward.
We’re bringing together the latest information backed by science and making it available and accessible to everyone who needs it.”

 

PROFESSOR ADAM FRIEDMAN
CO-CHAIR, SENSITIVE SKINCARE FACULTY,
PROFESSOR AND CHAIR OF DERMATOLOGY,
THE GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES

 

Faculty members include Adam Friedman (co-chair, U.S.), Giovanni Pellacani (Italy), Martina Kerscher (Germany), Aaron Farberg (U.S.), Flávia Alvim Sant’Anna Addor (Brazil), Belinda Welsh (Australia), Yan Wu (China), Flordeliz Abad-Casintahan (Philippines), Adelaide Hebert (U.S.), Xiang Leihong (China), Laurent Misery (France), Joachim Fluhr (Germany) and Leona Yip (Australia).

The faculty’s inaugural meeting took place at the European Academy of Dermatology and Venereology congress in Milan, where members also participated in a Galderma-sponsored symposium on sensitive skin insights and management approaches.

About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:
iChen W, Dai R, Li L. The prevalence of self‐declared sensitive skin: a systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2020 Aug;34(8):1779-88.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005039/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release

Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e

Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release

Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release

Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa

Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release

News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye